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Introduction
Myelodysplastic syndromes (MDS) represent a collection
of early hematopoietic progenitor cell clonal disorders charac-
terized by ineffective hematopoiesis and low peripheral
blood counts.1 Although lenalidomide, azacitidine and
decitabine are all Food and Drug Administration (FDA)-
approved agents to treat MDS in the US, allogeneic
hematopoietic cell transplantation has remained the only
potential cure for MDS patients.2
Increased apoptotic death of hematopoietic cells has been
observed in early MDS, and has been associated with ineffec-
tive hematopoiesis.3-4 Tumor necrosis factor alpha (TNF-α) is
a pro-inflammatory cytokine that inhibits normal
hematopoiesis and induces programmed cell death of both
normal total bone marrow cells and normal CD34+ cells.5
Several observations have suggested an important role of
TNF-α in the pathophysiology of low-risk MDS.6-9
Infliximab (Remicade®) is a chimeric human / murine anti-
body combining the variable region of the murine monoclon-
al antibody A2 recognizing human TNF-α and human
immunoglobulin G1 constant regions. Clinical phase III stud-
ies in rheumatoid arthritis and in Crohn’s disease have shown
that infliximab binds to TNF-α, prevents TNF-α binding to
both the p55 and p75 TNF receptors, and is effective in both
disorders.10-11 Dosages applied in most trials were 3 mg/kg,
5mg/kg or 10 mg/kg, given intravenously at weeks 0, 2 and 6,
and then every 4-8 weeks thereafter.10-11 Few data on the effi-
cacy of infliximab in MDS patients have been reported so far.
Stasi and Amadori observed sustained erythroid response in
2 of 2 patients with low-/intermediate-risk MDS, isolated
anemia, and elevated circulating levels of TNF-α, after admin-
istration of infliximab given intravenously at the dose of 3
mg/kg.12 Raza et al. administered infliximab at the dose of 5
mg/kg (n=18) or 10 mg/kg (n=19) intravenously every four
weeks for 4 cycles to patients with refractory anemia
(RA)/refractory anemia with ringed sideroblasts (RARS)
(n=28), or refractory anemia with excess blasts (RAEB, n=9).13
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Tumor-necrosis factor alpha activity has been correlated to
ineffective erythropoiesis in lower risk myelodysplastic syn-
dromes. Infliximab (Remicade®) is an anti-tumor necrosis fac-
tor alpha chimeric antibody that is used in the treatment of
patients with rheumatoid arthritis or Crohn’s disease. Forty-
six patients with myelodysplastic syndromes and a relatively
low risk of developing acute leukemia were included in a ran-
domized phase II study assessing the therapeutic activity of
two dosages of infliximab administration (3 mg/kg vs. 5
mg/kg). The primary end point was the response rate.
Responses were observed in 3 of 22 patients (13.1%) random-
ized to the 3 mg/kg arm, versus 0 of 21 patients randomized in
the 5 mg/kg arm. According to the statistical design of the cur-
rent study, neither of the two infliximab dose schedules tested
showed sufficient activity as a single agent in this cohort of
unselected patients with early myelodysplastic syndrome.
(ClinicalTrials.gov number, NCT00074074)
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ABSTRACT
The drug was generally well tolerated, and 8 patients
(including 3 patients given inflixamab at the dose of 5
mg/kg and 5 patients given infliximab at 10 mg/kg)
achieved hematologic responses. 
Here, we report the results of a randomized phase II
study assessing therapeutic activity and adverse event pro-
file of two dosages of infliximab administration (3 mg/kg
vs. 5 mg/kg) in patients with myelodysplastic syndrome
and a relatively low risk of developing acute leukemia. 
Design and Methods
Study design
Study design is detailed in the Online Supplementary Appendix.
Main eligibility criteria included MDS intermediate or good IPSS
risk score14 and FAB type RA, RARS, or RAEB with 10% or under
bone marrow blasts; no poor cytogenetic characteristics; 6 weeks
or over prior to randomization without treatment for MDS other
than supportive care only; WHO performance status 0-2; Hb <10
g/dL or RBC transfusion dependent and/or neutrophil count
<1.5¥109/L and/or platelet count <100¥109/L or platelet transfusion
dependent; no severe cardiac or pulmonary dysfunction; serum
bilirubin and creatinine ≤1.5 x ULN; and absence of current or
prior active or latent tuberculosis infection.15 Signed written
informed consent was obtained according to ICH/GCP and
national/local regulations. The study protocol was approved by
the EORTC Protocol Review Committee and by the Ethical
Committee of each participating center. Eligible patients were ran-
domized 1:1 to receive infliximab 3 mg/kg (arm A) or infliximab 5
mg/kg (arm B). Infliximab was injected intravenously on days 1, 15
and then every four weeks until Month 6 (for a total of 8 infu-
sions). 
Primary end point was the response rate (complete response,
partial response and hematologic improvement) as defined by
Cheson et al.16 Secondary end points included the definition of tox-
icity profile of infliximab in MDS patients and the duration of
response. Overall and progression-free survivals, although not
specifically indicated as secondary end points in the protocol,
were also evaluated prospectively.
Statistical analysis
The statistical design of the study is detailed in the Online
Supplementary Appendix. Briefly, the amended protocol was based
on a Simon 2-stage design. P0 was 15%; P1 was 35%; beta was
0.05; and alpha was 0.15. This implies entering and evaluating the
first 18 patients for each infliximab arm. If 2 responses or less were
observed (2 of 18=11.1%), the trial would conclude that infliximab
(at the given dose level, according to randomization) should not be
further investigated in this patient population, while if 3 responses
or more were observed, one should continue the accrual for 18
additional patients, in the arm(s) which passed the 1st step. Since
36 (2 x 18) patients with a follow up longer than six months were
already entered at the time of the amendment, an interim analysis
was performed on complete data for all these patients. The study
remained closed after the interim analysis given the demonstrated
lack of sufficient efficacy of the two schedules of infliximab eval-
uated (see below).
Statistical analyses
Survival duration was calculated from the date of randomiza-
tion until death irrespective of the cause. Progression-free survival
was calculated from the date of randomization until the date of
first progression or until death. The Kaplan-Meier method was
used to estimate survival-type distributions.17 The 95% confi-
dence interval of the median was obtained using the reflected
method.18 Cox’s Proportional Hazard Model has been used to
determine the prognostic importance of IPSS risk group (3-ordered
categorical variable) and to obtain an estimate of the treatment
hazard ratio (HR) adjusted by IPSS risk group along with its corre-
sponding 95% confidence interval (CI).17 Analyses were per-
formed according to the intent-to-treat principle. The cut-off date
was June 2010. SAS 9.2 statistical software (SAS Institute®, Cary,
North Carolina, USA) was used for analysis.
Results and Discussion
Patients’ characteristics
Between February 2004 and March 2006, a total of 46
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Table 1. Patients’ characteristics.
Treatment arm
3 mg/kg 5 mg/kg
(N=22) (N=21)
Sex
Male, N (%) 9 (40.9) 12 (57.1)
Female, N (%) 13 (59.1) 9 (42.9)
Age at randomization (years)
Median (range) 65.5 (50.0-83.0) 66.0 (39.0-91.0)
≤ 65, N (%) 11 (50.0) 10 (47.6)
66-75, N (%) 6 (27.3) 6 (28.6)
> 75, N (%) 5 (22.7) 5 (23.8)
WHO performance status:
0, N (%) 10 (45.5) 9 (42.9)
1, N (%) 12 (54.5) 12 (57.1)
French-American-British classification 
Refractory anemia, N (%) 6 (27.3) 11 (52.4)
Refractory anemia with ringed 9 (40.9) 2 (9.5) 
sideroblasts, N (%)
Refractory anemia with excess 7 (31.8) 8 (38.1)
blasts (<10%), N (%)
Cytogenetic risk group*
Good risk, N (%) 12 (54.5) 14 (66.7)
Intermediate, N (%) 6 (27.3) 4 (19.0)
Unknown /not done, N (%) 4 (18.2) 3 (14.3)
IPSS 
Low risk, N (%) 4 (18.2) 7 (33.3)
Intermediate 1, N (%) 16 (72.7) 11 (52.4)
Intermediate 2, N (%) 2 (9.1) 3 (14.3)
Blood value at randomization 
WBC, median (range), ¥109/L 3.2 (0.6-7.2) 3.6 (0.8-18.2)
Hb, median (range), g/dL 8.9 (6.2-13.3) 8.7 (5.6-10.6)
RBC transfusion dependency 18 (82) 18 (86)
or Hb <10g/dL, N (%)
Plt, median (range), ¥109/L 156 (14-533) 112 (4-463)
Plt transfusion dependency 7 (32) 9 (43)
or platelet < 100 ¥109/L, N (%)
Time from MDS diagnosis
to randomization (years)
<1, N (%) 4 (18.2) 6 (28.6)
1-<3, N (%) 8 (36.4) 5 (23.8) 
3-<5, N (%) 6 (27.3) 4 (19.0)
≥ 5, N (%) 4 (18.2) 6 (28.6)
Time from MDS diagnosis
to randomization (years)
Median (range) 2.5 (0.1 - 18.0) 2.8 (0.3 - 15.0)
* According to the IPSS classification.
patients were randomized by 17 centers. The study coor-
dinator considered 3 patients to be ineligible (2 patients
because of poor risk cytogenetics and the remaining
patient for bilirubin level > 1.5 x ULN). These patients
were excluded from all analyses. Patients’ characteristics
were well balanced in the two treatment arms with the
exception of a slight imbalance regarding IPSS score with
more good risk patients being randomized in the 5 mg/kg
arm (7 of 21) than in the 3 mg/kg arm (4 of 22) (Table 1). 
Adherence to protocol treatment
Treatment administration was generally performed
according to protocol guidelines (Online Supplementary
Appendix). 
Reasons for discontinuing the treatment
Median time to off-protocol treatment was 0.5 years in
both arms, while 14 of 22 (64%) patients in the 3 mg/kg
group versus 11 of 21 (52%) patients in the 5 mg/kg group
completed 8 courses of infliximab. In the 3 mg/kg group,
8 patients went prematurely off-protocol due to either dis-
ease progression (n=3), adverse event/toxicity (n=3) or
patient refusal (n=2). In the 5 mg/kg group, reasons for
going off-protocol before the normal completion of the
study included disease progression (n=7), death not due to
malignant disease (n=1), patient refusal (n=1), and other
(n=1).  
Adverse events
The incidence of grade 3 or over adverse events reported
during the treatment period was relatively low, apart for
grade 3-5 infections that occurred in 9 of 22 (41%) patients
in the 3 mg/kg arm versus in 4 of 21 (19%) patients in the
5 mg/kg arm. Two of these infections, both on 3 mg/kg,
were lethal, and have been considered as likely to be relat-
ed to protocol treatment. The maximum grade 3 or over
adverse events by treatment arm are shown in the Online
Supplementary Table S1. The fact that infliximab was rela-
tively well tolerated in both the 3 and 5 mg/kg arms apart
for grade 3-5 infections might open a window for further
studies combining TNF-α blockade with other MDS
active agents. Indeed, encouraging results have been
observed by Scott et al. by combining TNF-α blockade
with azacitidine19 or anti-thymocyte globulin.20
Activity and outcome
The response rate (complete remission, partial remission
or hematologic improvement) was low in both arms: 3 of
22 (13.6%) patients in the 3 mg/kg arm versus 0 of 21
patients in the 5 mg/kg arm (Table 2). For both arms, the
95% confidence interval of the response rate was 2.9-
34.9% and 0-16.1% for the 3 and 5 mg/kg arms, respec-
tively. This response rate did not cover the targeted rate of
35%. The 3 responders had either IPSS intermediate-1
(n=2) or intermediate-2 (n=1) and were randomized 0.4,
3.2 and 3.4 years after MDS diagnosis. As shown in Figure
1, the outcomes of the 5 patients with intermediate-2 IPSS
patients were poor, with 4 of them progressing on treat-
ment 45-76 days after randomization. If we exclude these
5 patients, the response rate was 2 of 20 patients (10%;
95% CI, 1.2%-31.7%) in the 3 mg/kg arm, versus 0 of 18
patients (0%; 95% CI, 0-18.5%) in the 5 mg/kg arm. Risk
of progression or death on treatment was associated with
Infliximab for early MDS
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Table 2. Outcome by treatment arm.
Treatment arm
3 mg/kg (N=22) 5 mg/kg (N=21)
N (%) N (%)
Best response
Complete response 1 (4.5) 0 (0.0)
Partial response 1 (4.5) 0 (0.0)
Hematologic improvement 1 (4.5) 0 (0.0) 
Stable disease 10 (45.5) 16 (76.2)
Progressive disease 8 (36.4) 4 (19.0)
Not evaluable 1 (4.5) 1 (4.8)
Survival status 
Alive 9 (40.9) 5 (23.8)
Dead 13 (59.1) 16 (76.2)
Cause of death
Progression 7 (31.8) 8 (38.1)
Toxicity 1 (4.5)1 2 (9.5)2
Cardiovascular 2 (9.1) 0 (0.0)
Other 3 (13.6)3 3 (28.6)4
Unknown   0 3
1Septic shock and cardiac infarction; 2toxicity attributed to lenalidomide therapy (n=1)
or to allogeneic hematopoietic stem cell transplantation with a sibling donor (n=1);
3pneumonia (n=1) and co-morbidity (n=2); 4car accident (n=1), infection with cardio-
vascular failure (n=1) and acute respiratory distress syndrome (n=1).
Figure 1. Progression-free survival from randomization according to
infliximab dosage arm (A) or IPSS score (B). P value given by the
Wald test (Cox’s model).
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a higher IPSS score (Figure 1) but not with a longer time
from diagnosis to randomization (Online Supplementary
Figure S1). The response rates observed in the current
study were lower than response levels observed in that
carried out by Raza et al. in which 8 of 37 patients (22%)
achieved a hematologic response.13 In agreement with our
data, Deeg et al. observed a low frequency of response
when etanercept (a soluble TNF-α receptor fusion protein;
Enbrel®) was administered alone in patients with MDS.21
The relatively long duration of MDS (2.7 years) might be
an explanation for the low response rates in our study,
since apoptosis plays a more important role in early MDS
than in more advanced disease. Furthermore, lower
response rate in patients with longer duration of MDS has
also been observed after treatment with lenalidomide or
immunosuppressive therapy.22-23 Taken together, these
observations support the hypothesis that TNF-α blockade
alone has insufficient activity in patients with MDS.
The median progression-free survival from randomiza-
tion was 0.6 (95% CI, 0.5-3.0) years in the 3 mg/kg arm
versus 1.6 (0.4- 3.4) years in the 5 mg/kg arm (Figure 1A),
while the median survival was 2.6 (1.9-not reached) years
versus 3.4 (2.2-5.3) years in the 3 mg/kg and 5 mg/kg arms,
respectively (Online Supplementary Figure 2A). As expected,
IPSS score was of prognostic importance for both progres-
sion-free (P=0.006; Figure 1B) and overall (P=0.04; Online
Supplementary Figure 2B) survival. The longer median pro-
gression-free and overall survival in the 5 mg/kg arm versus
the 3 mg/kg arm could be explained by the imbalance in
favor of the 5 mg/kg regarding the IPSS risk group. Indeed,
the estimated hazard ratio (5 mg/kg vs. 3 mg/kg) adjusted
by the IPSS risk group was 1.05 (95% CI, 0.52-2.11) years
for progression-free survival and 1.25 (95% CI, 0.60-2.60)
years for overall survival, respectively.
In summary, our results demonstrated that neither of
the two infliximab dose schedules tested in the current
study showed sufficient activity in unselected patients
with MDS and a relatively low risk of developing acute
leukemia to warrant further investigation as a single agent
in phase III studies.
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